E D Kharasch

2.9k total citations · 2 hit papers
25 papers, 2.1k citations indexed

About

E D Kharasch is a scholar working on Pharmacology, Oncology and Pediatrics, Perinatology and Child Health. According to data from OpenAlex, E D Kharasch has authored 25 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Pharmacology, 11 papers in Oncology and 6 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in E D Kharasch's work include Pharmacogenetics and Drug Metabolism (15 papers), Drug Transport and Resistance Mechanisms (7 papers) and Cancer Treatment and Pharmacology (4 papers). E D Kharasch is often cited by papers focused on Pharmacogenetics and Drug Metabolism (15 papers), Drug Transport and Resistance Mechanisms (7 papers) and Cancer Treatment and Pharmacology (4 papers). E D Kharasch collaborates with scholars based in United States, Germany and Netherlands. E D Kharasch's co-authors include Andrea Gaedigk, Todd C. Skaar, Teri E. Klein, Katrin Sangkuhl, Henry M. Dunnenberger, Julia Stingl, Christine Hoffer, Kelly E. Caudle, Cynthia A. Prows and J. Steven Leeder and has published in prestigious journals such as The Journal of Physiology, Journal of Pharmacology and Experimental Therapeutics and Anesthesiology.

In The Last Decade

E D Kharasch

25 papers receiving 2.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Clinical Pharmacogenetics Implementation Consortium Guidelines for Cytochrome P450 2D6 Genotype and Codeine Therapy: 2014 Update

2014 453 citations Kristine R. Crews, Andrea Gaedigk et al. Clinical Pharmacology & Therapeutics profile →
Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update

2016 450 citations Katrin Sangkuhl, JJ Swen et al. Clinical Pharmacology & Therapeutics profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
E D Kharasch United States	14	1.4k	569	387	343	286	25	2.1k
John T. Callaghan United States	17	879 0.6×	485 0.9×	268 0.7×	423 1.2×	328 1.1×	42	2.1k
JS Leeder United States	10	1.3k 1.0×	904 1.6×	451 1.2×	386 1.1×	281 1.0×	10	2.3k
Caroline Samer Switzerland	28	832 0.6×	440 0.8×	352 0.9×	283 0.8×	295 1.0×	107	2.5k
Su Duan United States	26	1.6k 1.2×	531 0.9×	761 2.0×	458 1.3×	534 1.9×	43	2.9k
Yoseph Caraco Israel	27	946 0.7×	296 0.5×	337 0.9×	264 0.8×	432 1.5×	102	2.3k
Séverine Crettol Switzerland	18	586 0.4×	454 0.8×	286 0.7×	186 0.5×	289 1.0×	40	1.5k
Robin E. Pearce United States	29	1.3k 1.0×	631 1.1×	621 1.6×	447 1.3×	467 1.6×	58	2.4k
Einosuke Tanaka Japan	25	1.0k 0.8×	316 0.6×	570 1.5×	319 0.9×	309 1.1×	139	2.3k
D. Gail McCarver United States	22	801 0.6×	680 1.2×	356 0.9×	239 0.7×	333 1.2×	30	2.0k
Jan van der Weide Netherlands	27	1.6k 1.1×	721 1.3×	616 1.6×	415 1.2×	553 1.9×	47	2.8k

Countries citing papers authored by E D Kharasch

Since Specialization

Citations

This map shows the geographic impact of E D Kharasch's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by E D Kharasch with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites E D Kharasch more than expected).

Fields of papers citing papers by E D Kharasch

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by E D Kharasch. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by E D Kharasch. The network helps show where E D Kharasch may publish in the future.

Co-authorship network of co-authors of E D Kharasch

This figure shows the co-authorship network connecting the top 25 collaborators of E D Kharasch. A scholar is included among the top collaborators of E D Kharasch based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with E D Kharasch. E D Kharasch is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Crews, Kristine R., Andrea Gaedigk, Henry M. Dunnenberger, et al.. (2014). Clinical Pharmacogenetics Implementation Consortium Guidelines for Cytochrome P450 2D6 Genotype and Codeine Therapy: 2014 Update. Clinical Pharmacology & Therapeutics. 95(4). 376–382. 453 indexed citations breakdown →

Blake, Catherine, E D Kharasch, Matthias Schwab, & Peter Nägele. (2013). A Meta-Analysis of CYP2D6 Metabolizer Phenotype and Metoprolol Pharmacokinetics. Clinical Pharmacology & Therapeutics. 94(3). 394–399. 93 indexed citations

Hicks, J. Kevin, Jesse J. Swen, Caroline F. Thorn, et al.. (2013). Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants. Clinical Pharmacology & Therapeutics. 93(5). 402–408. 327 indexed citations

Swen, JJ, et al.. (2013). Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic. 9 indexed citations

Kharasch, E D, et al.. (2011). Concurrent Assessment of Hepatic and Intestinal Cytochrome P450 3A Activities Using Deuterated Alfentanil. Clinical Pharmacology & Therapeutics. 89(4). 562–570. 12 indexed citations

Kharasch, E D, et al.. (2011). Sensitivity of Intravenous and Oral Alfentanil and Pupillary Miosis as Minimal and Noninvasive Probes for Hepatic and First-Pass CYP3A Induction. Clinical Pharmacology & Therapeutics. 90(1). 100–108. 23 indexed citations

Kharasch, E D. (2008). Adverse Drug Reactions With Halogenated Anesthetics. Clinical Pharmacology & Therapeutics. 84(1). 158–162. 34 indexed citations

Kharasch, E D, et al.. (2008). Mechanism of Ritonavir Changes in Methadone Pharmacokinetics and Pharmacodynamics: I. Evidence Against CYP3A Mediation of Methadone Clearance. Clinical Pharmacology & Therapeutics. 84(4). 497–505. 65 indexed citations

Kharasch, E D, et al.. (2008). Mechanism of Ritonavir Changes in Methadone Pharmacokinetics and Pharmacodynamics: II. Ritonavir Effects on CYP3A and P-Glycoprotein Activities. Clinical Pharmacology & Therapeutics. 84(4). 506–512. 76 indexed citations

10.

Templeton, Ian E., Kenneth E. Thummel, E D Kharasch, et al.. (2007). Contribution of Itraconazole Metabolites to Inhibition of CYP3A4 In Vivo. Clinical Pharmacology & Therapeutics. 83(1). 77–85. 103 indexed citations

11.

Kharasch, E D, et al.. (2005). Single-point sampling for assessment of constitutive, induced, and inhibited cytochrome P450 3A activity with alfentanil or midazolam. Clinical Pharmacology & Therapeutics. 78(5). 529–529. 44 indexed citations

12.

Spracklin, Douglas K., et al.. (2003). Concordance between trifluoroacetic acid and hepatic protein trifluoroacetylation after disulfiram inhibition of halothane metabolism in rats. Acta Anaesthesiologica Scandinavica. 47(6). 765–770. 4 indexed citations

13.

Oda, Y. & E D Kharasch. (2001). Metabolism of methadone and levo-alpha-acetylmethadol (LAAM) by human intestinal cytochrome P450 3A4 (CYP3A4): potential contribution of intestinal metabolism to presystemic clearance and bioactivation.. PubMed. 298(3). 1021–32. 64 indexed citations

14.

Kharasch, E D, et al.. (2000). Contribution of CYP2E1 and CYP3A to acetaminophen reactive metabolite formation. Clinical Pharmacology & Therapeutics. 67(3). 275–282. 255 indexed citations

15.

Kharasch, E D, et al.. (1996). Clinical Sevoflurane Metabolism and Disposition. Survey of Anesthesiology. 40(2). 78–78. 2 indexed citations

16.

Kharasch, E D, Douglas S. Mautz, & Andrew Bowdle. (1994). VARIABILITY IN ALFENTANIL PHARMACOKINETICS. Anesthesiology. 81(SUPPLEMENT). A382–A382. 1 indexed citations

17.

Kharasch, E D, et al.. (1994). Clinical Enflurane Metabolism by Cytochrome P-450 2EI. Survey of Anesthesiology. 38(6). 315–315. 2 indexed citations

18.

Novak, Raymond, et al.. (1988). Nitrofurantoin-stimulated proteolysis in human erythrocytes: a novel index of toxic insult by nitroaromatics.. Journal of Pharmacology and Experimental Therapeutics. 247(2). 439–444. 17 indexed citations

19.

Kharasch, E D, et al.. (1987). ATRIAL NATRIURETIC PEPTIDE RND THE RENAL EFFECTS OF PEEP VENTILATION. Anesthesiology. 67(3). A330–A330. 1 indexed citations

20.

Kharasch, E D, Alan M. Mellow, & Eugene M. Silinsky. (1981). Intracellular magnesium does not antagonize calcium‐dependent acetylcholine secretion.. The Journal of Physiology. 314(1). 255–263. 29 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact